We had demonstrated marked reductions in phosphorylated ERK1/2 and cyclin D1, key effectors of the MAPK pathway, consistent with previous findings in cervical [16], gall-bladder [14], non-small-cell lung [57], and triple-negative breast-cancer systems [58]. The gene discussed is CCND1; the disease is medical procedure.